ArticleExperimental and therapeutic medicine2014
Monoamine neurotransmitters and fibroblast growth factor-2 in the brains of rats with post-stroke depression.
Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Effects of noninvasive brain stimulation in the treatment of poststroke depression: an overview of systematic reviews.Frontiers in neurologyPooled it
- Traditional Chinese medicine interventions for post-stroke emotional disorders: a protocol for network meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2026Article
- Role of Fibroblast Growth Factors in Neurological Disorders: Insight into Therapeutic Approaches and Molecular Mechanisms.Molecular neurobiology · 2025Review
- Neuritin Controls Axonal Branching in Serotonin Neurons: A Possible Mediator Involved in the Regulation of Depressive and Anxiety Behaviors via FGF Signaling.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- The effectiveness of five-element music therapy for post-stroke depression: A systematic review and meta-analysis.Heliyon · 2024Article
- The Role of the Dopamine System in Post-Stroke Mood Disorders in Newborn Rats.International journal of molecular sciences · 2023Article
- Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review.International journal of molecular sciences · 2022Review
- Natural Products for the Treatment of Post-stroke Depression.Frontiers in pharmacology · 2022Review
- Prevalence, Severity, and Predictors of Poststroke Depression in a Prospective Cohort of Jordanian Patients.Stroke research and treatment · 2022Article
- Microglia Involves in the Immune Inflammatory Response of Poststroke Depression: A Review of Evidence.Oxidative medicine and cellular longevity · 2022Review
- Fibroblast Growth Factors in Depression.Frontiers in pharmacology · 2019Review
- Executive (dys)function after stroke: special considerations for behavioral pharmacology.Behavioural pharmacology · 2018Review
- Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats.Scientific reports · 2017Article
- Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.Seminars in cell & developmental biology · 2016Review
- Combined use of spatial restraint stress and middle cerebral artery occlusion is a novel model of post-stroke depression in mice.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the changes in the levels of serotonin (5-HT), dopamine (DA), norepinephrine (NE) and fibroblast growth factor-2 (FGF-2) in the brains of rats with post-stroke depression (PSD). A rat model of stroke was established by middle cerebral artery occlusion and the rats were randomly divided into two groups: Control and modification groups. The rats in the modification group had PSD, while the rats in the control group had experienced a stroke only. The PSD model was established by applying chronic mild stress to the individually housed rats. High-performance liquid chromatography was used to detect the levels of 5-HT, DA and NE, while western blotting was used to detect the FGF-2 protein expression levels in the frontal lobe and hippocampus. Quantitative polymerase chain reaction was also used to determine the mRNA expression levels of FGF-2 in the frontal lobes of the two groups. The levels of 5-HT, DA and NE in the frontal lobe and hippocampus of the rats in the PSD group were significantly lower than the levels observed in the rats in the stroke group (P<0.01). In addition, protein expression levels of FGF-2 in the frontal lobe of the rats in the PSD group were significantly lower when compared with the control group rats (P<0.01), however, the protein expression levels of FGF-2 in the hippocampus did not exhibit a statistically significant difference (P>0.05). The mRNA expression levels of FGF-2 in the frontal lobe of the rats in the modification group were significantly lower than the levels in the control group rats (P<0.01). Therefore, reduced levels of monoamine neurotransmitters and FGF-2 expression in the brains of rats with PSD are associated with the incidence of PSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.